ZUG, Switzerland, Oct. 06, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (OCS) (“Oculis”), a global biopharmaceutical company focused on innovations addressing neuro-ophthalmic diseases with significant ...

Privosegtor is advancing in the registrational PIONEER program across 2 key optic neuropathies, representing an unaddressed potential market of $7 billion in the U.S. Privosegtor achieved an average ...

Objectives Glaucoma is an optic neuropathy caused by the gradual degeneration of retinal ganglion cells. This study aimed to investigate the knowledge, attitude and practice (KAP) towards glaucoma ...

BUFFALO, N.Y. — A small percentage of patients taking the extraordinarily popular GLP-1 medications have experienced vision problems, but a direct causal link with the drugs has not been established.

Please provide your email address to receive an email when new articles are posted on . A 65-year-old woman presented to the New England Eye Center with 4 weeks of decreased vision and 6 months of ...

What The Case Report Says: A case of COVID-19 with severe ocular neuropathy and panuveitis (inflammation) is reported in this article. Authors: Jean Marc Perone, M.D., of Metz-Thionville Regional ...

Breakthrough therapy designation granted as Company advances the PIONEER registrational program in optic neuropathies to create a potential ...

Chronic rhinosinusitis (CRS) significantly affects ophthalmologic health but remains largely manageable, according to a ...

ZUG, Switzerland, Oct. 14, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (OCS) (“Oculis”), a global biopharmaceutical company focused on developing innovations for ophthalmic and neuro-ophthalmic ...

Please provide your email address to receive an email when new articles are posted on . The odds of developing dry eye disease were nearly four-times higher in patients with moderate to severe ...